Ident. | Authors (with country if any) | Title |
---|
000032 (2020) |
Ming Niu [République populaire de Chine] ; Rui-Lin Wang [République populaire de Chine] ; Zhong-Xia Wang [République populaire de Chine] ; Ping Zhang [République populaire de Chine] ; Zhao-Fang Bai [République populaire de Chine] ; Jing Jing [République populaire de Chine] ; Yu-Ming Guo [République populaire de Chine] ; Xu Zhao [République populaire de Chine] ; Xiao-Yan Zhan [République populaire de Chine] ; Zi-Teng Zhang [République populaire de Chine] ; Xue-Ai Song [République populaire de Chine] ; En-Qiang Qin [République populaire de Chine] ; Jia-Bo Wang [République populaire de Chine] ; Xiao-He Xiao [République populaire de Chine] | [Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking]. |
000050 (2020) |
Cai-Xia Yan [République populaire de Chine] ; Jia Li [République populaire de Chine] ; Xin Shen [République populaire de Chine] ; Li Luo [République populaire de Chine] ; Yan Li [République populaire de Chine] ; Ming-Yuan Li [République populaire de Chine] | [Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019]. |
000078 (2020) |
Yuefei Jin [République populaire de Chine] ; Haiyan Yang [République populaire de Chine] ; Wangquan Ji [République populaire de Chine] ; Weidong Wu [République populaire de Chine] ; Shuaiyin Chen [République populaire de Chine] ; Weiguo Zhang [République populaire de Chine] ; Guangcai Duan [République populaire de Chine] | Virology, Epidemiology, Pathogenesis, and Control of COVID-19. |
000091 (2020) |
Erwan Sallard [France] ; François-Xavier Lescure [France] ; Yazdan Yazdanpanah [France] ; France Mentre [France] ; Nathan Peiffer-Smadja [France] | Type 1 interferons as a potential treatment against COVID-19 |
000149 (2020) |
Y J Duan [République populaire de Chine] ; Q. Liu [République populaire de Chine] ; S Q Zhao [République populaire de Chine] ; F. Huang [République populaire de Chine] ; L. Ren [République populaire de Chine] ; L. Liu [République populaire de Chine] ; Y W Zhou [République populaire de Chine] | The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 (COVID-19) and Its Research Progress in Forensic Toxicology. |
000166 (2020) |
Yuxin Yan [République populaire de Chine] ; Woo In Shin [Malaisie] ; Yoong Xin Pang [République populaire de Chine] ; Yang Meng [République populaire de Chine] ; Jianchen Lai [République populaire de Chine] ; Chong You [République populaire de Chine] ; Haitao Zhao [États-Unis] ; Edward Lester [Royaume-Uni] ; Tao Wu [République populaire de Chine] ; Cheng Heng Pang [République populaire de Chine] | The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. |
000186 (2020) |
Jiayu Liao [États-Unis] ; George Way [États-Unis] ; Vipul Madahar [États-Unis] | Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies. |
000286 (2020) |
Michele Costanzo ; Maria Anna Rachele De Giglio ; Giovanni Nicola Roviello | SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. |
000306 (2020) |
Lance Turtle [Royaume-Uni] | Respiratory failure alone does not suggest central nervous system invasion by SARS-CoV-2. |
000330 (2020) |
Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis] | Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status |
000418 (2020) |
Balamurugan Shanmugaraj [Thaïlande] ; Konlavat Siriwattananon [Thaïlande] ; Kittikhun Wangkanont [Thaïlande] ; Waranyoo Phoolcharoen [Thaïlande] | Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). |
000506 (2020) |
Li Runfeng [République populaire de Chine] ; Hou Yunlong [République populaire de Chine] ; Huang Jicheng [République populaire de Chine] ; Pan Weiqi [République populaire de Chine] ; Ma Qinhai [République populaire de Chine] ; Shi Yongxia [République populaire de Chine] ; Li Chufang [République populaire de Chine] ; Zhao Jin [République populaire de Chine] ; Jia Zhenhua [République populaire de Chine] ; Jiang Haiming [République populaire de Chine] ; Zheng Kui [République populaire de Chine] ; Huang Shuxiang [République populaire de Chine] ; Dai Jun [République populaire de Chine] ; Li Xiaobo [République populaire de Chine] ; Hou Xiaotao [République populaire de Chine] ; Wang Lin [République populaire de Chine] ; Zhong Nanshan [République populaire de Chine] ; Yang Zifeng [République populaire de Chine] | Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). |
000586 (2020) |
P. Conti [Italie] ; C E Gallenga [Italie] ; G. Tetè [Italie] ; Al Caraffa [Italie] ; G. Ronconi [Italie] ; A. Younes [Italie] ; E. Toniato [Italie] ; R. Ross [États-Unis] ; S K Kritas [Grèce] | How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. |
000719 (2020) |
Jason N. Katz [États-Unis] ; Shashank S. Sinha [États-Unis] ; Carlos L. Alviar [États-Unis] ; David M. Dudzinski [États-Unis] ; Ann Gage [États-Unis] ; Samuel B. Brusca [États-Unis] ; M Casey Flanagan [États-Unis] ; Timothy Welch [États-Unis] ; Bram J. Geller [États-Unis] ; P Elliott Miller [États-Unis] ; Sergio Leonardi [Italie] ; Erin A. Bohula [États-Unis] ; Susanna Price [Royaume-Uni] ; Sunit-Preet Chaudhry [États-Unis] ; Thomas S. Metkus [États-Unis] ; Connor G. O'Brien [États-Unis] ; Alessandro Sionis [Espagne] ; Christopher F. Barnett [États-Unis] ; Jacob C. Jentzer [États-Unis] ; Michael A. Solomon [États-Unis] ; David A. Morrow [États-Unis] ; Sean Van Diepen [Canada] | Disruptive Modifications to Cardiac Critical Care Delivery During the Covid-19 Pandemic: An International Perspective. |
000722 (2020) |
Liying Dong [République populaire de Chine] ; Shasha Hu [République populaire de Chine] ; Jianjun Gao [République populaire de Chine] | Discovering drugs to treat coronavirus disease 2019 (COVID-19). |
000747 (2020) |
Md Insiat Islam Rabby [Malaisie] | Current Drugs with Potential for Treatment of COVID-19: A Literature Review. |
000790 (2020) |
Jaime A. Teixeira Da Silva | Convalescent plasma: A possible treatment of COVID-19 in India |
000793 (2020) |
Giuseppe A. Marraro [Italie] ; Claudio Spada | Consideration of the respiratory support strategy of severe acute respiratory failure caused by SARS-CoV-2 infection in children. |
000839 (2020) |
Chunchen Wu [République populaire de Chine] ; Wenzhong Yang [République populaire de Chine] ; Xiaoxue Wu [République populaire de Chine] ; Tianzhu Zhang [République populaire de Chine] ; Yaoyao Zhao [République populaire de Chine] ; Wei Ren [République populaire de Chine] ; Jianbo Xia [République populaire de Chine] | Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women |
000848 (2020) |
Anuj Sharma [États-Unis] | Chloroquine Paradox May Cause More Damage Than Help Fight COVID-19. |
000872 (2020) |
Adriano Nunes Kochi [Italie] ; Ana Paula Tagliari [Suisse] ; Giovanni Battista Forleo [Italie] ; Gaetano Michele Fassini [Italie] ; Claudio Tondo [Italie] | Cardiac and arrhythmic complications in patients with COVID-19. |
000879 (2020) |
Bingwen Liu [République populaire de Chine] ; Min Li [République populaire de Chine] ; Zhiguang Zhou [République populaire de Chine] ; Xuan Guan [États-Unis] ; Yufei Xiang [République populaire de Chine] | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? |
000921 (2020) |
Ennio Giulio Favalli [Italie] ; Francesca Ingegnoli [Italie] ; Orazio De Lucia [Italie] ; Gilberto Cincinelli [Italie] ; Rolando Cimaz [Italie] ; Roberto Caporali [Italie] | COVID-19 infection and rheumatoid arthritis: Faraway, so close! |
000940 (2020) |
Ludmila Prokunina-Olsson [États-Unis] ; Noémie Alphonse [Royaume-Uni] ; Ruth E. Dickenson [Royaume-Uni] ; Joan E. Durbin [États-Unis] ; Jeffrey S. Glenn [États-Unis] ; Rune Hartmann [Danemark] ; Sergei V. Kotenko [États-Unis] ; Helen M. Lazear [États-Unis] ; Thomas R. O'Brien [États-Unis] ; Charlotte Odendall [Royaume-Uni] ; Olusegun O. Onabajo [États-Unis] ; Helen Piontkivska [États-Unis] ; Deanna M. Santer [Canada] ; Nancy C. Reich [États-Unis] ; Andreas Wack [Royaume-Uni] ; Ivan Zanoni [États-Unis] | COVID-19 and emerging viral infections: The case for interferon lambda. |
000954 (2020) |
Bonnie Ky ; Douglas L. Mann [États-Unis] | COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. |
000961 (2020) |
Pengfei Sun [République populaire de Chine] ; Xiaosheng Lu [République populaire de Chine] ; Chao Xu [République populaire de Chine] ; Yanjin Wang [République populaire de Chine] ; Wenjuan Sun [République populaire de Chine] ; Jianing Xi [République populaire de Chine] | CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19). |
000981 (2020) |
Abid Haleem [Inde] ; Mohd Javaid [Inde] ; Raju Vaishya [Inde] ; S. G. Deshmukh [Inde] | Areas of academic research with the impact of COVID-19 |
000997 (2020) |
Canrong Wu [République populaire de Chine] ; Yang Liu [République populaire de Chine] ; Yueying Yang [République populaire de Chine] ; Peng Zhang [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Yali Wang [République populaire de Chine] ; Qiqi Wang [République populaire de Chine] ; Yang Xu [République populaire de Chine] ; Mingxue Li [République populaire de Chine] ; Xingzhou Li [République populaire de Chine] ; Mengzhu Zheng [République populaire de Chine] ; Lixia Chen [République populaire de Chine] ; Hua Li [République populaire de Chine] | Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |
000A22 (2020) |
Donald C. Hall ; Hai-Feng Ji | A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |